jak2 2 56 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
95
Structured Review
Cell Signaling Technology Inc
jak2 2 56
Jak2 2 56, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 133 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak2+2+56/Stat5+Rabbit+mAb/pmc07720771__oncotarget___11___4411___s001-2-364-350
Average 95 stars, based on 133 article reviews
Jak2 2 56, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 133 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/jak2+2+56/Stat5+Rabbit+mAb/pmc07720771__oncotarget___11___4411___s001-2-364-350
Average 95 stars, based on 133 article reviews
jak2 2 56 - by Bioz Stars,
2026-09
95/100 stars
Images
Related Articles
Mutagenesis:Article Title: Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico Article Snippet: 18 73 F CMML1 KRAS, NRAS, ASXL1, EZH2, and TET2 19 66 F CMML1 KRAS, RUNX1, and TET2 20 82 M CMML1 KRAS, SRSF2, and TET2 21 74 M CMML2 NPM1, PTPN11, SF3B1, TET2, and DNMT3A 22 68 F CMML1 NRAS, ASXL1, and TET2 23 74 M CMML2 RUNX1 and SF3B1 24 73 M CMML1 SETBP1, SRSF2, and ZRSR2 25 86 M CMML1 SF3B1 and ASXL1 26 82 M CMML1 SRSF2 and RUNX1 27 81 M CMML1 SRSF2 and TET2 28 75 F CMML1 SRSF2 and TET2 29 67 M CMML1 SRSF2 and TET2 30 80 F CMML1 SRSF2, TET2, and NF1 31 69 M CMML1 TET2 and DNMT3A 32 70 F CMML1 TET2 and KIT 33 89 M CMML1 TET2 and ZRSR2 34 82 M CMML1 TET2, ASXL1, NRAS, and SRSF2 35 80 M CMML2 U2AF1 and GATA2 36 67 M CMML1 ZRSR2 and TET2 37 71 M CMML1 ASXL1, CBL, SRSF2, TET2, PDGFRA, and RUNX1 38 67 M CMML1 ASXL1, JAK2, SRSF2, TET2, and WT1 39 79 M CMML1 ASXL1, NF1, SETBP1, and SRSF2 40 74 F CMML2 ASXL1, PHF6, and CBL 41 80 F CMML1 ASXL1, TET2, and NRAS 42 78 M CMML1 CBL and TET2 43 70 F CMML1 CBL, SRSF2, TET2, and NF1 44 92 F CMML1 NF1, SRSF2, and ETV6 45 70 F CMML1 No mutations 46 72 M CMML1 NRAS, SRSF2, and TET2 47 70 M CMML2 NRAS, TET2, and ZRSR2 48 78 M CMML1 RUNX1 and TET2 49 87 M CMML1 SRSF2 and TET2 50 54 M CMML1 SRSF2 and TET2 51 88 M CMML1 SRSF2, TET2, BCOR, and SETBP1 52 76 F CMML1 TET2 and EZH2 53 71 M CMML1 TET2 and ZRSR2 54 78 M CMML1 TET2 and ZRSR2 55 67 M CMML1 TET2 and ZRSR2 56 89 M CMML1 TET2, ZRSR2, and EZH2 Supplementary Table 2: Major classes of gene mutation in Hispanic CMML patients Major class of gene mutation Gene Frequency of mutation Epigenetic Control TET2 40/56 (71%) ASXL1 16/56 (29%) DNMT3A 7/56 (13%) EZH2 5/56 (7%) SETBP1 3/56 (5%) IDH1 1/56(2%) IDH2 1/56 (2%) RAD21 1/56 (2%) Control:Article Title: Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico Article Snippet: 18 73 F CMML1 KRAS, NRAS, ASXL1, EZH2, and TET2 19 66 F CMML1 KRAS, RUNX1, and TET2 20 82 M CMML1 KRAS, SRSF2, and TET2 21 74 M CMML2 NPM1, PTPN11, SF3B1, TET2, and DNMT3A 22 68 F CMML1 NRAS, ASXL1, and TET2 23 74 M CMML2 RUNX1 and SF3B1 24 73 M CMML1 SETBP1, SRSF2, and ZRSR2 25 86 M CMML1 SF3B1 and ASXL1 26 82 M CMML1 SRSF2 and RUNX1 27 81 M CMML1 SRSF2 and TET2 28 75 F CMML1 SRSF2 and TET2 29 67 M CMML1 SRSF2 and TET2 30 80 F CMML1 SRSF2, TET2, and NF1 31 69 M CMML1 TET2 and DNMT3A 32 70 F CMML1 TET2 and KIT 33 89 M CMML1 TET2 and ZRSR2 34 82 M CMML1 TET2, ASXL1, NRAS, and SRSF2 35 80 M CMML2 U2AF1 and GATA2 36 67 M CMML1 ZRSR2 and TET2 37 71 M CMML1 ASXL1, CBL, SRSF2, TET2, PDGFRA, and RUNX1 38 67 M CMML1 ASXL1, JAK2, SRSF2, TET2, and WT1 39 79 M CMML1 ASXL1, NF1, SETBP1, and SRSF2 40 74 F CMML2 ASXL1, PHF6, and CBL 41 80 F CMML1 ASXL1, TET2, and NRAS 42 78 M CMML1 CBL and TET2 43 70 F CMML1 CBL, SRSF2, TET2, and NF1 44 92 F CMML1 NF1, SRSF2, and ETV6 45 70 F CMML1 No mutations 46 72 M CMML1 NRAS, SRSF2, and TET2 47 70 M CMML2 NRAS, TET2, and ZRSR2 48 78 M CMML1 RUNX1 and TET2 49 87 M CMML1 SRSF2 and TET2 50 54 M CMML1 SRSF2 and TET2 51 88 M CMML1 SRSF2, TET2, BCOR, and SETBP1 52 76 F CMML1 TET2 and EZH2 53 71 M CMML1 TET2 and ZRSR2 54 78 M CMML1 TET2 and ZRSR2 55 67 M CMML1 TET2 and ZRSR2 56 89 M CMML1 TET2, ZRSR2, and EZH2 Supplementary Table 2: Major classes of gene mutation in Hispanic CMML patients Major class of gene mutation Gene Frequency of mutation Epigenetic Control TET2 40/56 (71%) ASXL1 16/56 (29%) DNMT3A 7/56 (13%) EZH2 5/56 (7%) SETBP1 3/56 (5%) IDH1 1/56(2%) IDH2 1/56 (2%) RAD21 1/56 (2%) Biomarker Discovery:Article Title: Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico Article Snippet: 18 73 F CMML1 KRAS, NRAS, ASXL1, EZH2, and TET2 19 66 F CMML1 KRAS, RUNX1, and TET2 20 82 M CMML1 KRAS, SRSF2, and TET2 21 74 M CMML2 NPM1, PTPN11, SF3B1, TET2, and DNMT3A 22 68 F CMML1 NRAS, ASXL1, and TET2 23 74 M CMML2 RUNX1 and SF3B1 24 73 M CMML1 SETBP1, SRSF2, and ZRSR2 25 86 M CMML1 SF3B1 and ASXL1 26 82 M CMML1 SRSF2 and RUNX1 27 81 M CMML1 SRSF2 and TET2 28 75 F CMML1 SRSF2 and TET2 29 67 M CMML1 SRSF2 and TET2 30 80 F CMML1 SRSF2, TET2, and NF1 31 69 M CMML1 TET2 and DNMT3A 32 70 F CMML1 TET2 and KIT 33 89 M CMML1 TET2 and ZRSR2 34 82 M CMML1 TET2, ASXL1, NRAS, and SRSF2 35 80 M CMML2 U2AF1 and GATA2 36 67 M CMML1 ZRSR2 and TET2 37 71 M CMML1 ASXL1, CBL, SRSF2, TET2, PDGFRA, and RUNX1 38 67 M CMML1 ASXL1, JAK2, SRSF2, TET2, and WT1 39 79 M CMML1 ASXL1, NF1, SETBP1, and SRSF2 40 74 F CMML2 ASXL1, PHF6, and CBL 41 80 F CMML1 ASXL1, TET2, and NRAS 42 78 M CMML1 CBL and TET2 43 70 F CMML1 CBL, SRSF2, TET2, and NF1 44 92 F CMML1 NF1, SRSF2, and ETV6 45 70 F CMML1 No mutations 46 72 M CMML1 NRAS, SRSF2, and TET2 47 70 M CMML2 NRAS, TET2, and ZRSR2 48 78 M CMML1 RUNX1 and TET2 49 87 M CMML1 SRSF2 and TET2 50 54 M CMML1 SRSF2 and TET2 51 88 M CMML1 SRSF2, TET2, BCOR, and SETBP1 52 76 F CMML1 TET2 and EZH2 53 71 M CMML1 TET2 and ZRSR2 54 78 M CMML1 TET2 and ZRSR2 55 67 M CMML1 TET2 and ZRSR2 56 89 M CMML1 TET2, ZRSR2, and EZH2 Supplementary Table 2: Major classes of gene mutation in Hispanic CMML patients Major class of gene mutation Gene Frequency of mutation Epigenetic Control TET2 40/56 (71%) ASXL1 16/56 (29%) DNMT3A 7/56 (13%) EZH2 5/56 (7%) SETBP1 3/56 (5%) IDH1 1/56(2%) IDH2 1/56 (2%) RAD21 1/56 (2%) |